Medibio Ltd
ASX:MEB

Watchlist Manager
Medibio Ltd Logo
Medibio Ltd
ASX:MEB
Watchlist
Price: 0.02 AUD Market Closed
Market Cap: 122m AUD
Have any thoughts about
Medibio Ltd?
Write Note

Medibio Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medibio Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Medibio Ltd
ASX:MEB
Cash & Cash Equivalents
AU$214.1k
CAGR 3-Years
-36%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
4DMedical Ltd
ASX:4DX
Cash & Cash Equivalents
AU$30.6m
CAGR 3-Years
-28%
CAGR 5-Years
58%
CAGR 10-Years
N/A
CogState Ltd
ASX:CGS
Cash & Cash Equivalents
$30.1m
CAGR 3-Years
8%
CAGR 5-Years
56%
CAGR 10-Years
41%
Pro Medicus Ltd
ASX:PME
Cash & Cash Equivalents
AU$60.1m
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
16%
Medadvisor Ltd
ASX:MDR
Cash & Cash Equivalents
AU$15.6m
CAGR 3-Years
30%
CAGR 5-Years
29%
CAGR 10-Years
45%
Alcidion Group Ltd
ASX:ALC
Cash & Cash Equivalents
AU$11.8m
CAGR 3-Years
-22%
CAGR 5-Years
30%
CAGR 10-Years
11%
No Stocks Found

Medibio Ltd
Glance View

Market Cap
122m AUD
Industry
Health Care

Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. The firm offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company offers a software called MEBsleep, a medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. The Company’s subsidiaries include Bioprospect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Medibio Limited USA, Invatec Health Pty Ltd and Annapanna Pty Ltd.

MEB Intrinsic Value
0.001 AUD
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Medibio Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
214.1k AUD

Based on the financial report for Jun 30, 2023, Medibio Ltd's Cash & Cash Equivalents amounts to 214.1k AUD.

What is Medibio Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-49%

Over the last year, the Cash & Cash Equivalents growth was -79%. The average annual Cash & Cash Equivalents growth rates for Medibio Ltd have been -36% over the past three years , -49% over the past five years .

Back to Top